Table 2.
Proteoforms obtained after heavy chain analysis on the 4 monoclonal antibodies analysed. Average experimental masses on triplicate analysis were reported together with theoretical average masses and average mass accuracies for each proteoform. Relative abundances were calculated based on the MS signal intensities in the triplicate analysis. Masses were calculated accounting for C-term lysine clipping unless stated otherwise.
| mAbs | Modifications/Glycoforms | Experimental mass (Da) | Theoretical average mass (Da) | Mass difference (ppm) | Relative abundance (%) |
|---|---|---|---|---|---|
| BEV | Unglycosylated | 49718.8 | 49718.7 | 1.3 | 1.5 |
| A1G0F | 50961.2 | 50960.8 | 6.7 | 2.1 | |
| A2G0 | 51017.5 | 51017.9 | 7.1 | 0.4 | |
| A2G0F | 51163.8 | 51164.0 | 5.0 | 82.0 | |
| A2G1 | 51180.0 | 51180.0 | 1.3 | 1.4 | |
| A2G1F | 51325.9 | 51326.2 | 4.8 | 12.0 | |
| A2G2F | 51488.3 | 51488.3 | 1.3 | 0.4 | |
| A2S1G1F | 51746.2 | 51745.6 | 12.1 | 0.2 | |
| TRA | M5 | 50372.6 | 50373.2 | 12.5 | 0.7 |
| A1G0F | 50398.3 | 50398.3 | 1.3 | 0.6 | |
| A2G0 | 50455.0 | 50455.3 | 6.8 | 3.9 | |
| A2G0F | 50601.2 | 50601.5 | 6.1 | 51.0 | |
| A2G1 | 50617.4 | 50617.5 | 1.6 | 0.6 | |
| A2G1F | 50763.3 | 50763.6 | 6.5 | 38.1 | |
| A2G2F | 50925.3 | 50925.8 | 8.2 | 5.1 | |
| INF | M5 | 50605.5 | 50605.4 | 3.4 | 1.2 |
| 1x C-term lysine, M5 | 50734.1 | 50733.5 | 10.1 | 2.1 | |
| A1G0F | 50758.2 | 50758.6 | 7.4 | 1.3 | |
| A2G0 | 50815.3 | 50815.7 | 7.2 | 1.1 | |
| A2G0F | 50833.5 | 50833.6 | 1.8 | 17.8 | |
| 1x C-term lysine, A2G0F | 50962.0 | 50961.8 | 4.5 | 48.2 | |
| A2G1F | 50995.3 | 50995.8 | 8.6 | 11.3 | |
| 1x C-term lysine, A2G1F | 51123.3 | 51123.9 | 12.3 | 16.2 | |
| A2G2F | 51158.4 | 51157.9 | 9.4 | 0.8 | |
| RIT | Gln-- > Pyro-Glu, A2G0F | 50513.9 | 50514.3 | 8.1 | 46.2 |
| Gln-- > Pyro-Glu, A2G1F | 50676.1 | 50676.4 | 7.0 | 46.4 | |
| Gln-- > Pyro-Glu, A2G2F | 50838.1 | 50838.6 | 9.9 | 7.4 |